Junjing Guo
Hematology & Oncology · New York, NYNPI 1700348984
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 24.3% of the total. 2025 is the largest year on record at $1,944, 5.2 times the $376 reported in 2023.
Across 57 payments — averaging $53.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$735
- AstraZeneca$609
- Recordati_rare_diseases_inc.$307
- Amgen$241
- Johnson & Johnson$192
- Pfizer$154
- plus $790 from 17 others
What the payments were for
- Food & beverage$2,92997%
- Education$993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 8 | $735 |
| AstraZeneca(2 entities) | 12 | $609 |
| Recordati_rare_diseases_inc. | 4 | $307 |
| Amgen | 2 | $241 |
| Johnson & Johnson | 3 | $192 |
| Pfizer | 2 | $154 |
| Incyte Corporation | 3 | $149 |
| Servier Pharmaceuticals LLC | 2 | $147 |
| Springworks Therapeutics, Inc. | 2 | $59 |
| Sumitomo Pharma America, Inc. | 2 | $51 |
| Novartis | 2 | $46 |
| Taiho Oncology, Inc. | 2 | $45 |
| Bristol Myers Squibb | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 1 | $36 |
| Array Biopharma Inc | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Syndax Pharmaceuticals, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Eisai Inc. | 1 | $25 |
| Exelixis Inc. | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $23 |
| Puma Biotechnology, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,028 in reported general payments places this provider in the 60th percentile of 967 hematology & oncology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 19 | $267,072 |
| Abiraterone Acetate | 24 | $134,846 |
| Anastrozole | 12 | $183 |
| Prednisone | 28 | $100 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.